GlassScriptPhysician profile
Ryan W Yealy
NPI 1528298593
$164,361.65
in general payments reported to CMS, 2019-2025
24 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,284 · 2020: $467 · 2021: $3,214 · 2022: $25K · 2023: $68K · 2024: $51K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $51K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $31K · Consulting Fee: $28K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $6,702 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $50,899.11 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $30,550.00 |
| Consulting Fee | $27,740.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,500.00 |
| Food and Beverage | $6,702.00 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $122,071.35 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $31,251.74 | 2019-2025 | Cequa |
| Shire North American Group INC | $3,485.00 | 2019 | |
| Allergan, INC. | $2,384.31 | 2019-2022 | |
| Abbvie INC. | $975.69 | 2022-2024 | Alphagan P, Lumigan |
| Tarsus Pharmaceuticals, INC. | $960.07 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $565.91 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $458.21 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $420.53 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Coopervision INC. | $311.89 | 2019-2025 | Myday Contact Lens |
| Alcon Vision LLC | $299.03 | 2019-2025 | Tryptyr, Precision7, Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $295.37 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $223.16 | 2022-2024 | Acuvue |
| Dompe US, INC. | $180.82 | 2021-2025 | Oxervate |
| Oyster Point Pharma, INC. | $175.37 | 2022-2025 | Tyrvaya |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $120.02 | 2019 | |
| Tearlab Corp | $43.08 | 2021 | |
| Sight Sciences, INC. | $24.36 | 2022 | |
| Eyevance Pharmaceuticals LLC | $23.47 | 2022 | |
| Spark Therapeutics, INC. | $21.54 | 2019 | |
| Plexus Optix, INC. | $21.29 | 2019 | |
| Thea Pharma INC. | $16.82 | 2022 | |
| Oasis Medical, INC. | $16.67 | 2024 | Oasis Tears |
| Maculogix, INC. | $15.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Yealy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.